Coya Therapeutics, Inc. (COYA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Keay Nakae from Chardan Capital reiterated the rating on the stock to a Buy and gave it a $11.00 price target.
Keay Nakae has given his Buy rating due to a combination of factors surrounding Coya Therapeutics, Inc.’s recent developments and future prospects. Key among these is the company’s successful completion of enrollment in a phase II trial led by investigators from the Houston Methodist Hospital. This study is evaluating the use of low dose IL-2 in patients with mild to moderate Alzheimer’s Disease. A key aspect of this trial is its focus on determining whether more frequent dosing can result in an improved PK/PD, thereby enhancing the function of Treg and minimizing the cyclic effect observed with longer dose intervals.
Furthermore, Nakae’s rating takes into account the company’s strategic positioning of COYA 301 as a foundation therapy. This means that other compounds could potentially be combined with it to boost their immunotherapeutic impacts. Additionally, the company plans to file an IND for COYA 302 in the first quarter of 2024, which represents a combined therapy designed to enhance the effects of low-dose IL-2. This combined approach is expected to further inhibit the activation of pro-inflammatory effector T cells and macrophages, thus down-regulating the secretion of pro-inflammatory cytokines. This strategic direction, coupled with the financial backing from the Gates Foundation and the Alzheimer’s Association, have all contributed to Nakae’s Buy rating for Coya Therapeutics.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Coya Therapeutics, Inc. (COYA) Company Description:
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Read More on COYA:
